FDA, Novo Nordisk and Shortage

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Senators questioned Novo Nordisk CEO Lars Jørgensen on Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs, which are cheaper in other countries. The CEO of ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...